NCT07123129View on ClinicalTrials.gov

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Advanced Malignancy
Interventions
DRUG

SHR-7782 Injection

SHR-7782 injection.

Trial Locations (2)

100020

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY